NBIX Stock Recent News

New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and mental health advocate, Carnie Wilson. The campaign aims to support people struggling with the uncontrolled movements of tardive dyskinesia, an involuntary movement disorder associated with the use of antipsychotic medications, by sharing stories of courage and resilience in seeking diagnosis and treatment.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q1 2025 Results Conference Call May 5, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Dr. Eiry Roberts - Chief Medical Officer Conference Call Participants Paul Matteis - Stifel Tazeen Ahmad - Bank of America Phil Nadeau - TD Cowen Brian Abrahams - RBC Capital Markets David Amsellem - Piper Sandler Anupam Rama - JPMorgan Josh Schimmer - Cantor Jay Olson - Oppenheimer Cory Kasimov - Evercore Brian Skorney - Baird Marc Goodman - Leerink Partners Mike Riad - Morgan Stanley Ash Verma - UBS Myles Minter - William Blair Laura Chico - Wedbush Operator Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode.

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago.

INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO , May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance. "We delivered a record number of new patient starts for INGREZZA, which is especially impressive given the typically challenging first quarter.

-- Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements1 SAN DIEGO , May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and reinforcing the need for routine screening, earlier diagnosis and treatment. The findings revealed that 80% of people living with tardive dyskinesia surveyed wished they had been screened for the condition earlier, and 86% wished their provider had discussed available treatment options for their uncontrolled movements sooner.1*   The survey results come during Tardive Dyskinesia (TD) Awareness Week, May 4-10.

Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568 (NBI-'568), an investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.

SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.

Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern SAN DIEGO , April 24, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a post-hoc analysis from two 48-week studies, the KINECT® 3 extension and KINECT® 4, demonstrating the long-term safety profile and robust efficacy of INGREZZA® (valbenazine) capsules in adults aged 65 years and older with tardive dyskinesia (TD) in The Journal of Clinical Psychiatry. This represents the first and only published peer-reviewed analysis of a vesicular monoamine transporter 2 inhibitor for the treatment of TD in older adults (≥65 years), a group at higher risk for TD and associated consequences.

Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024.